Will GDUFA III Curtail Priority Assessments?
Executive Summary
US FDA's expedited pathway for generics seems to provide more benefits for amendments than for original ANDAs.
You may also be interested in...
US FDA's Generics Program Reaches 'Steady State' Milestone
OGD Director Uhl says program is now in balance between the number of submissions and agency review actions.
Let's Get Real – ANDA Approval Likely Takes More Than Two Years, US FDA Says
Office of Generic Drugs Director Kathleen Uhl calls a two-cycle approval timeline a realistic expectation for ANDA approval, but would not say that most ANDAs will fall into the paradigm.
Unhappy With GDUFA II? Note It For GDUFA III, FDA Says
US agency says it is implementing generic drug user fee program as outlined in commitment letter and any changes should be discussed at negotiations for the 2022 renewal.